What Are 340b Covered Entities as per the 340b Drug Pricing Program?

Hospitals across the US rely on the 340B Drug Pricing Program to maximize their budgets. The program allows eligible hospitals to acquire outpatient drugs at discounted rates. However, many hospital administrators still pose the same fundamental question: which hospitals qualify as 340B covered entities? 

We will address that question by providing an explanation of how covered entities use the program.

Understanding the 340b Drug Pricing Program

340B Drug Pricing Program came into existence in 1992 by act of Congress. As per section 340B of the Public Health Service Act (PHSA), drug makers have to provide discounts on outpatient drugs to certain eligible healthcare entities. Through the program, US hospitals that cater to uninsured and poor people can utilize the funds more efficiently.

The 340B program works without the assistance of taxpayer dollars. Instead, manufacturers agree to offer these discounts as a condition for having their drugs covered under Medicaid. This structure lets hospitals reinvest savings directly into patient care.

Who Qualifies as 340b Covered Entities

340B covered entities comprise a variety of healthcare organizations. The list includes:

• Critical Access Hospitals (CAHs)

• Rural Referral Centers (RRCs)

• Sole Community Hospitals (SCHs)

• Disproportionate Share Hospitals

• Free-standing cancer hospitals

• Federally qualified health centers and certain specialty clinics

Every covered entity has to abide by the 340B eligibility requirement. The eligibility rules are set by the Health Resources and Services Administration (HRSA). HRSA looks at the following factors before granting the 340B status:

• Patient population

• Hospital classification

• Medicare or Medicaid disproportionate share status

Thus, it is necessary for hospitals to register and recertify their status regularly to keep their place in the program.

Why 340b Drug Discounts Matter for Hospitals

Rural and safety net hospitals often run on thin margins. 340B drug discounts free up funds that hospitals can redirect toward staffing, equipment, and expanded services. A single quarter of properly captured savings can fund a new pharmacy hire or cover the cost of updated patient monitoring equipment.

Many hospital finance teams treat the 340B program as a background function. That approach leaves money on the table. Hospitals that actively manage their 340B accounts consistently capture more value than facilities that treat the program as an afterthought.

The Orphan Drug Challenge for 340b Covered Entities

Not every drug qualifies for 340B pricing. Since 2013, HRSA rules have excluded certain orphan drugs from 340B eligibility for Critical Access Hospitals, Rural Referral Centers, Sole Community Hospitals, and freestanding cancer hospitals. This exclusion applies only when a facility uses the orphan drug to treat the rare condition for which it received its original designation. When the same drug treats a different condition, covered entities can often still access 340B drug discounts.

This distinction creates real complexity for hospital teams. Pharmacy and finance staff must track which drugs carry orphan designations, monitor how each drug gets used, and document every purchase correctly. A missed detail can mean lost savings or a flagged item during an HRSA or manufacturer audit.

How Covered Entities Can Protect Savings and Stay 340b Compliant

Staying on top of the 340B Drug Pricing Program takes more than good intentions. Hospitals that succeed tend to follow a few consistent practices.

• Review orphan drug lists every quarter, since manufacturer rules shift often

• Build a clear documentation process that pharmacy and billing teams can follow together

• Train staff regularly on current 340B requirements and orphan drug exclusions

• Partner with specialists who track manufacturer changes full time

Hospitals that follow these steps reduce audit risk and protect the savings they already earn.

Common Misconceptions About 340b Covered Entities

Here are some common misconceptions about 340B covered entities:

First Misconception

Some hospital administrators assume the 340B program works the same way for every facility. That assumption is confusing. Here are the distinctions:

• A CAH faces different orphan drug rules than a Disproportionate Share Hospital. 

• A RRC may qualify for savings that a specialty clinic cannot access at all. 

Thus, understanding your specific entity type matters as much as understanding the program itself.

Second Misconception

One of the other myths about 340B covered entities is the belief regarding audits.

Some teams believe that a clean audit history means their processes will always hold up. Manufacturer pricing rules shift often, and HRSA guidance updates on its own schedule. A process that worked well last year can fall out of step within a few quarters. Hospitals that build flexibility into their compliance approach avoid this trap.

Third Misconception

The third myth has to do with size. Some smaller hospitals located in rural communities tend to think that the savings achieved through Section 340B only make a difference for big healthcare systems. This is not necessarily true. 

A rural facility operating on a tight margin can feel the impact of captured savings far more directly than a large system with multiple revenue streams. Every eligible dollar carries real weight for these hospitals.

Work With a Team That Understands 340b Covered Entities

340B Orphan Drug Solutions focuses on one corner of this program, orphan drug compliance and savings recovery. Dr. Lisa Nezneski, PharmD, BCPS, leads the practice from Orlando and works with hospitals nationwide, including small rural facilities and larger regional systems. Her team has helped 340B covered entities capture more than 500 million dollars in orphan drug savings.

The service builds a custom drug list for each facility, integrates split billing software, and delivers quarterly updates as manufacturer rules change. Clients get direct access to a specialist rather than a call center, along with job aids and ongoing support built around their existing workflow.

Schedule a compliance review today to see how your hospital can capture every eligible dollar under the 340B Drug Pricing Program.

Frequently Asked Questions

Q1. What Is the Difference Between 340b Covered Entities and 340b Contract Pharmacies?

Q2. How often do 340B eligibility requirements change?
Ans: HRSA updates guidance periodically, and manufacturer pricing rules can shift quarterly. Hospitals should review their status and drug lists on a regular schedule to stay current.

Q3. Do all covered entities qualify for orphan drug discounts under the 340B program?
Ans: No, it is not necessary. Critical Access Hospitals, Rural Referral Centers, Sole Community Hospitals, and free-standing cancer hospitals face orphan drug exclusions for certain drugs used to treat their designated rare condition.